What is Aravive, Inc. (ARAV)?

Aravive, Inc. (ARAV) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ARAV?

The current price of ARAV is $0.04. Prices are updated in real time on Stocks360.

What is ARAV's price-to-earnings (PE) ratio?

ARAV's trailing twelve-month PE ratio is -0.02, based on current price and earnings per share data available on Stocks360.

What is ARAV's market capitalization?

ARAV's market capitalization is $2,949,860.00, placing it in the small-cap tier.

Aravive, Inc. (ARAV)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.04

Market Cap

$2.95M

PE (TTM)

-0.02

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.19

Day Range

$0.04 – $0.05

52-wk Range

$0.04 – $2.46

Avg Volume

N/A

Volume

4.04M

Aravive, Inc. (ARAV) is a publicly traded company in the Healthcare sector. Latest price: $0.04. Market cap $2.95M. Trailing PE -0.02. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 20, 2024

EPS $-0.46 vs est. $-0.08

Missed by $0.38

Proprietary Signals

Signal snapshot temporarily unavailable.

About Aravive, Inc.

Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma. Aravive also has AVB-S6 in its pipeline, a soluble Fc-fusion protein aimed at blocking the activation of the same GAS6-AXL pathway. Beyond internal development, Aravive has forged strategic partnerships. This includes a collaboration with WuXi Biologics (Hong Kong) Limited to develop novel, high-affinity bispecific antibodies targeting cancer and fibrosis. Furthermore, a license agreement with 3D Medicines Inc. grants rights to develop and commercialize products featuring batiraxcept as the sole active ingredient for human oncological diseases across mainland China, Taiwan, Hong Kong, and Macau.…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.02×
P/S (TTM)	0.32×
P/B	0.14×
P/FCF (TTM)	-0.05×
EV / EBITDA	0.63×
EV / Sales	-4.87×
Earnings Yield	-5548.17%
Free Cash Flow Yield	-2206.55%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$44.47M
Net Income (TTM)	-$163.66M
Free Cash Flow (TTM)	-$60.21M
Net Debt	-$47.42M
Working Capital	$35.60M
Gross Margin	-632.60%
Operating Margin	-775.28%
Net Margin	-885.64%
Return on Equity	-306.06%
Return on Invested Capital	-161.69%